Providence St. Joseph Health

Providence St. Joseph Health Digital Commons
Earle A. Chiles Research Institute Fellowship
Program

Oregon Academic Achievement

4-29-2020

Manual Scalp Cooling in Early Stage Breast Cancer: Value of
Caretaker Training and Patient-Reported Experience to Optimize
Efficacy and Patient Selection
Manaz Rezayee
Providence Portland Medical Center, Manaz.Rezayee@providence.org

Nikki Moxon
Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR,
Nicole.Moxon@providence.org

Staci Mellinger
Earle A. Chiles Research Institute, Portland, OR; Providence Cancer Institute, Portland, OR,
Staci.Mellinger@providence.org

Amanda Y Seino
Medical Oncology, Earle A. Chiles Research Institute, Providence Cancer Institute,
Amanda.Seino@providence.org
Follow this and additional works at: https://digitalcommons.psjhealth.org/cancer_institute_fellowships

Nicole E. Fredich

Providence
Portland
medical
Center, nicole.fredrich@providence.org
Part of the
Oncology
Commons

See next page forCitation
additional authors
Recommended
Rezayee, Manaz; Moxon, Nikki; Mellinger, Staci; Seino, Amanda Y; Fredich, Nicole E.; Kelly, Tracy L.;
Mulligan, Susan; Rossi, Patrick; Uche, Ijeoma; Urba, Walter; Conlin, Alison; Ruzich, Janet; and Page, David
B, "Manual Scalp Cooling in Early Stage Breast Cancer: Value of Caretaker Training and Patient-Reported
Experience to Optimize Efficacy and Patient Selection" (2020). Earle A. Chiles Research Institute
Fellowship Program. 1.
https://digitalcommons.psjhealth.org/cancer_institute_fellowships/1

This Poster is brought to you for free and open access by the Oregon Academic Achievement at Providence St.
Joseph Health Digital Commons. It has been accepted for inclusion in Earle A. Chiles Research Institute Fellowship
Program by an authorized administrator of Providence St. Joseph Health Digital Commons. For more information,
please contact digitalcommons@providence.org.

Authors
Manaz Rezayee, Nikki Moxon, Staci Mellinger, Amanda Y Seino, Nicole E. Fredich, Tracy L. Kelly, Susan
Mulligan, Patrick Rossi, Ijeoma Uche, Walter Urba, Alison Conlin, Janet Ruzich, and David B Page

This poster is available at Providence St. Joseph Health Digital Commons: https://digitalcommons.psjhealth.org/
cancer_institute_fellowships/1

Manual Scalp Cooling in Early Stage Breast Cancer:
Value of Caretaker Training and Patient-Reported Experience to Optimize Efficacy and Patient Selection
Manaz Rezayee, Nicole Moxon R.N., Staci Mellinger R.N., Amanda Y. Seino, Nicole E. Fredrich, Tracy L. Kelly, Susan Mulligan M.A., Patrick Rossi M.D., Ijeoma Uche M.D., Walter J. Urba M.D. Ph.D., Alison K. Conlin M.D. M.P.H., Janet Ruzich D.O., David B. Page M.D.

Background

Results

• Chemotherapy-induced alopecia (CIA) is a common and emotionally distressing adverse effect of curative-intent chemotherapy
regimens in early stage breast cancer, resulting in physical and psychological impact on quality of life (1, 2)
• Potential mechanism of action is thought to be associated with reduced chemotherapy exposure related to local vasoconstriction,
and/or direct metabolic effects on hair follicle. (1, 2)
• Although FDA-approved machine-based scalp cooling devices, such as the Paxman® and DigniCap® systems, is effective for
reduction and/or prevention of CIA; however, availability is geographically limited. (3, 4)
• Manual cold-cap based systems are alternative systems that may also be effective (64.7%; n=55/85) and can be accessed by
motivated patients regardless of geographic location. (5)
• In prospective trials of manual cold capping, dedicated research staff have been responsible for cold-cap implementation,
whereas there are limited prospective data on outcomes in real-world settings. (1,5)
What is Penguin Cold Cap?
o Penguin Cold Cap is a portable scalp cooling system, which employs Crylon gel-filled caps that are cooled on dry ice, fitted
onto the scalp, and exchanged every 20-30 minutes by a caretaker.
• We evaluated the feasibility of caretaker-administered cold-cap efficacy following structured standardized training, and utilized
patient-reported subjective outcomes to develop a clinical tool to facilitate patient selection.

• 12 patients were enrolled and underwent training; 2 patients withdrew consent before initiating treatment (10 evaluable patients).
Efficacy: Scalp Cooling, Hair Loss and Safety
• 80% (n=8/10) of evaluable patients achieved the primary efficacy endpoint of <50% hair loss with Dean’s Alopecia scores of 02 (Table 1). Trial failures reported in 2 patients (20%) due to pre-mature treatment discontinuation.
• Patient-reported head cover usage (scarf/hat) for concealing hair loss was reported in only 1 patient (ACT; Dean’s Score: 2).
• Only 1 (out of 16; 6.25%) adverse event was possibly related to cold-capping (grade 1 head sore).
Secondary Endpoint: PROs
• As expected with chemotherapy, declines in global health status were observed; however, post-treatment global health
estimates are numerically favorable relative to estimates from other published cold cap studies.
• We observed an improvement in emotional function and future perspective (BR-23) at post-treatment visit relative to baseline.
• Notable improvements measured at time of exit interview were also seen in physical, role, and social functioning.
Exploratory Endpoint: Exit Interviews
• 80% (n=8/10) participated in the optional exit interview, including one subject who had prematurely discontinued cold-capping.
• All subjects(100%; n=8/8) mentioned importance of the training session, specifically the hands-on portion with majority (62.5%;
n=5/8) believed success was dependent on training session and cold caps were safe, effective and feasible (75%; n=6/8).
• Majority (87.5%; n=7/8) speculated QOL would decrease without capping citing less community support/social interactions,
hair loss (“chemo head”), financial, and negative impacts on career, privacy, self-esteem, and self-image.
• We analyzed the interview responses to identify thematic effects of cold-capping that could be dichotomized as beneficial
versus harmful (Figure 2). Prevalent themes identified included: privacy, perception (self-image/identity), distraction from cancer,
dependence on others and practical resources).
• These effects were then used to develop a clinical instrument to inform patients of the subjective costs and benefits of coldcapping (figure 3).
Figure 1: Primary endpoint efficacy via photographs from different angles comparing

Methods
A small pilot study (n=10) was conducted to evaluate the feasibility and efficacy of manual cold-capping.
Figure 1: Overview of Trial Process
Key eligibility criteria included:
• ≥18 years of age and informed consent
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Standardized Training:
• Prior to commencing therapy, one or more caretaker(s) were designated to assist with cold capping and underwent
standardized training by certified research staff.
• Training included didactic and hands-on simulation to optimize proper cold capping use and technique.
• Participants were provided structured training prior to the first treatment, but were not provided additional training or support
during the remainder of treatment.
• Cold-cap temperatures determined by hair type (fine/medium hair: -28°C to -30°C; thick hair: -30°C to -32°C).
Primary Endpoint:
o 30-day post-treatment hair retention using the Dean’s alopecia score (<50% hair loss, score 0-2 on 5-point scale)
Secondary Endpoints:
Figure 2: Patient Experience with Cold Caps Every Treatment Day
• Patient-reported outcomes:
1. Pre-Cooling
2. Infusion
3. Post-Infusion
o QOL assessments:
Ø Was it Worth it? (WIWI?)
• Starts 50 minutes
• Cap change every
• Caps change
prior to infusion.
30 minutes
every 30 minutes
Ø EORTC QLQ-C30
for 4 hours.
• Cap change every
Ø QLQ-BR23
20 minutes x 2.
Ø Body Image Scale (BIS)
o CTCAE v4.0 toxicity and patient-reported wig/head cover use
o Subjective patient experience (obtained by standardized exit interviews.
Statistical Design:
o Primary outcome was reported as the proportion of efficacy-evaluable subjects who retained >50% of their hair at 30
days post-treatment (Dean’s scale 0-2).
o Modified intention-to-treat (ITT) analysis whereby all subjects receiving at least 75% of prescribed chemotherapy dose
were considered evaluable.
o No pre-defined thresholds were set for declaring success as this was a pilot assessment to collect objective and
subjective data.
o Paired 2-sample t-tests (5% two-way alpha) were conducted to identify significant deviations in the mean, with the intent
of obtaining descriptive data, therefore no corrections were made for multiple comparisons.

baseline and the final post-treatment Dean’s Alopecia score with (A) 6 cycles of
TCH/P chemotherapy, while (B) and (C) both received 8 cycles of ACT/HP.

Table 1: Final Dean’s Alopecia Score with 2 treatment
discontinuations (ie trial failures) noted by asterisk.
Arm

Regimen

Arm 1
n=3

ACT/HP

Arm 2
n=5

TCH/P

Arm 3
n=1
Arm 4
n=1

Final Dean’s Alopecia Score

0.0

T/H

0: 1/1 (100%)

1.0

0: 4/10 (40%)
1: 3/10 (30%)
2: 3/10 (30%)*

0.8

This Study

QLQBR23

a Although

• Ability to reverse refusal of chemotherapy
• Financial stability via ability to maintain career
• Normal social interactions
• Improved emotional and/or social well-being
• Ability to share when ready and willing

• Became more self-conscious
• Decreased confidence

Perception
(Self-Image/Identity)

Control and continue “normal” life due to
ability to conceal diagnosis
• Conceal until ready and ability to choose resulting in:
• Improved emotional and/or mental well-being
• Prioritize self and ask for help when needed
• Improve self-esteem, image and confidence
• Decrease in self-consciousness
• Maintain career resulting in improved financial health
• ”Normal” perception:
• Inclined to be more social (increased social interactions)
• Helps to cope and maintain hope and strength
• Lack of change in life
The only positive part of the whole process
• Establishing “normal” appearance and/or helping cope with
diagnosis
• Better prioritize self and ask for help when needed
• Increased social interaction
• Ability to ignore diagnosis
• Obtain a bit of control over life

Emotionally and/or physically exhausting to
endure long cold-capping process in addition
to treatment and may feel a lack of control
• May be more stressful and anxiety provoking to
undergo this long and extensive process
• Negative impacts due to the repetitious nature of
cold-capping and/or decreased self-confidence

• Presence of additional and consistent family support
• Support that may have otherwise been lacking
• Family felt useful in helping with battle against cancer
• Helps to cope and maintain hope and strength
• Better prioritize self and ask for help when needed

Do you find it important to share your diagnosis with others when you are ready to?
Are you okay with people frequently touching your head to help put the cold-cap on?
Are you okay with the possibility of others observing you because of increased attention as a
result of cold-capping?
Due to regularly being touched and/or public cap changes, you may become more selfconscious and/or anxious with a potential decrease in confidence. Are you okay with
having these forms of invasion of privacy in order to preserve your hair?

Perception (Self-Image/Identity)

Distraction from
Cancer

Diverted focus away from treatment
• Couldn’t move on and/or grieve as hair loss
(thinning) occurs throughout
• More self-conscious and decreased self-confidence
• Additional stress and/or anxiety
• Discomfort in the beginning
• Disagreements with research staff

Practical Resources

Difficulty obtaining help due to huge
commitment
• May feel like bothering others just to help you
• May put negative pressure on caretakers and cause
them to be overwhelmed, stressed or anxious
• Finding right person (detail-oriented with physical
strength)

These are necessary throughout the whole process regardless of the impact:
• Atleast 1 designated caretaker available at all infusions
• Financial planning to ensure all costs are covered because it is costly
• Someone to pick up dry ice prior to chemotherapy infusion
• Having enough and/or dedicated space designated for cold-capping

Do you think your appearance impacts how you feel (when you look better you feel better)?
Do you think in looking “normal” you may obtain the ability to continue working?

Distraction from Cancer
Do you think preserving your hair will help you cope with a cancer diagnosis?
Do you think in keeping your hair you may feel like you have some control over your life?
Do you think focusing on cold-capping instead of treatment will help you in the process of
grieving and/or moving on?
If you were to lose your hair, would you more easily convince yourself to stay home instead
of going out?

Dependence on Others
Are you okay with completely depending on your caretaker for cold-capping as it is shown to
be impacted by caretaker technique?
Do you think having additional caretaker support in this regard will help you?

Practical Resources

Conclusion

Absolute Change

Other Studies
Paxman
DigniCap SCb,7
SC & no wig
SC & wig
Baseline
4th cycle
68.5
60.3
70.1
65.7
Sca,8

This Study

Other Studies

Pre- to Post Tx

No SC (CT MLS)c,6

DigniCap SCb,7

-1.66

-1.80

-4.4

86.1
82.0
69.0
82.8
73.4

-16.66
-23.33
9.17
-15
-13.34

-7.40
-3.89
6.73
-6.50
-5.35

-7.3
-3.7
-1.7
-7.6
-9.6

---

---

-3.34

2.49

---

Post-Tx

Exit Interview

70.83

69.17

64.58

94
80
70
83.33
81.67

77.34
56.67
79.17
68.33
68.33

84.17
77.08
69.79
64.58
70.84

77.9
62.0
72.1
72.4
79.7

70.7
52.2
67.8
65.0
71.7

93.4
85.7
70.7
90.4
83.0

33.33

13.5

18.9

23.33

Is it important for you to conceal your diagnosis?

Do you think in keeping your hair you may feel “normal?”

Dependence on
Others

Increased social interaction and established
a sense of belonging and/or community

Yes

If necessary, do you have additional support to pickup dry ice the night prior to infusion?

Pre-Tx

26.67

Forms of invasion of privacy via:
• Constantly being touched
• Public cap changes

Privacy

Privacy

Do you have the financial funds necessary to proceed with Cold-Cap Therapy?

Absolute Mean

QLQC30

Forms of preservation of privacy via:
• Appearance (keeping hair)
• Concealing diagnosis until ready

No

Do you have at least one designated caretaker or local consultant capable of cold-capping to
attend all infusion sessions?

Table 2 (Below): Secondary endpoint assessment via patient-reported questionnaire
results during 3 different instances (pre-treatment, post-treatment and exit interview) in
this study and comparative QOL data obtained from other studies with absolute QOL
mean values and calculated changes from baseline. Average follow-up at time of
interview was 281 days (range: 30 to 548 days). High scores in global health status
and functional scales represent better/higher QOL. Higher scores in symptom scales
represent having higher symptoms (worse/lower QOL).

Global Health Status
Functional Scale
Physicald
Role
Emotionald
Cognitive
Social
Symptom Scale
Financial Difficulties
Functional Scales
Body Image
Future Perspective
Symptom Scale
Upset by Hair Lossd

Negative and/or Unfavorable

Positive and/or Beneficial

Would Cold-Capping Therapy Be Appropriate For You?

0.8

2: 1/1 (100%)*

Subset

Effects of Preventing/Reducing CIA via Cold-Capping

Figure 3: Clinical instrument assessing
appropriateness for patient to pursue cold-capping.

1.0

TC

Total:
n = 10

Figure 2: Representation of prevalent themes of effects of preventing
and/or reducing CIA via cold-capping identified during post-treatment exit
interviews.
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Results

71.67
33.33

67.5
46.67

64.58
41.67

74.2
53.8

65.3
52.2

76.9
48.9

66.0
59.6

-4.17
13.34

-15.24
12.14

-10.9
10.7

3.33

30

4.17

21.8

43.7

19.4

38.9

26.67

14.38

19.5

this study did indicate collecting QOL data prior to chemotherapy, baseline data was not provided and it was reported that no statistical differences were found between with and
without scalp cooling (SC), except for cognitive functioning in QLQ-C30 (85.9 vs 80.7; p=0.05).
b This study focused on patients receiving an adjuvant treatment with anthracycline.
c
This study utilized a model-derived statistical analysis for the QOL data and provided the mean least square (MLS) differences between time of diagnosis and 2-year post-diagnosis visit.
d
Paired two-sample t-test between baseline and 30-day post-treatment demonstrated statistical significance (<0.05).

• This pilot study affirms the safety and efficacy of manual cold-capping for the prevention of CIA in early stage
breast cancer, and highlights its potential in the setting of both anthracycline-containing and anthracycline-sparing
chemotherapy regimens. It also highlights the considerable costs and effort associated with cold-capping.
• It also demonstrates the potential utility of structured training to maximize efficacy and patient satisfaction.
• Selected patients with early stage breast cancer may benefit subjectively from cold-capping. In cataloguing the
subjective cold-cap patient accounts, prevalent themes potentially contributing to the determination of clinical
benefit versus harm were identified.
• Using these observations, we propose a clinical decision-making tool that may enable patients to weigh the
subjective benefits and drawbacks of cold-capping, so patients can make informed decisions regarding cold-cap
implementation.
• Further research is necessary to validate our preliminary findings, and to further define the utility of the coldcapping decision-making tool.
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